2017-15: The effect of treatment strategy on presumed ocular histoplasmosis syndrome (POHS)
Presumed ocular histoplasmosis syndrome (POHS) is considered to be an inflammatory, non-infectious disease of the choroid and retina. No consensus exists on the use of anti-inflammatory drugs, systemic or local. Only when a central macular inflammatory focus develops, it is generally treated with a high boost of systemic steroids. The most frequent complication, i.e. secondary choroidal neovascularisation (CNV), is treated with anti-VEGF injections.The disease has a recurrent nature, with recurrence intervals varying from months to years. Although new lesions during recurrence tend to occur as satellite lesion, next to old scars, there is no consensus of using chronic anti-inflammatory drugs in high risk patients to prevent irreversible visual acuity loss.
In this study we will collect preliminary data on the effect of systemic and local immune suppression on the number and duration of recurrence episodes, and on the occurrence of secondary CNV.